GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                               
                            
                                
                                                                Synonyms: compound 68 [WO2010002845A2] | HMPL-813 | HMPL813
                                 
                                                         
                            Compound class: 
                                                            Synthetic organic
                                 
                                
                                    
                                        Comment: Epitinib (HMPL-813) is a selective EGFR tyrosine kinase inhibitor that is under investigation for potential to treat solid tumours in China. Epitinib appears to be a 'pseudo' INN. As of July 2021 there had been no submission to the WHO for the INN. The chemical structure is claimed in patent WO2010002845A2 [1].
                                    
                                 
                            
                            
                          
                                
                                    
                                
                          
                                   
                                   
                                  
                                    
                                    
                                     | 
                                    
                                        
                                         
  | 
                                    
                                
                                |||||||||||||||||||||||||||||||||||
| No information available. | 
Summary of Clinical Use ![]()  | 
                                                        
| Epitinib is in early stage clinical evaluation for anti-tumour potential. | 
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References | 
| NCT03231501 | HMPL-813 in Treating Patients With Glioblastoma | Phase 1 Interventional | Hutchison Medipharma Limited | ||
| NCT02590952 | A Phase I Study of Epitinib(HMPL-813) in Patients With Advanced Solid Tumors | Phase 1 Interventional | Hutchison Medipharma Limited | ||